Overall survival
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Ryosuke Kita, Ken Kato, Ryunosuke Machida, Yoshinori Ito, Hiroyuki Daiko, Hirofumi Kawakubo, Keita Sasaki, Haruhiko Fukuda, Yasue Kimura, Kohei Akiyoshi, Kazuo Koyanagi, Hiroki Hara, Keiko Minashi, Kenji Amagai, Tetsuya Abe, Satoru Matsuda, Takahiro Tsushima, Hiroya Takeuchi
Ann Surg Oncol 33(6) 5327-5338
BACKGROUND: The optimal timing of surgery following neoadjuvant therapy in esophageal squamous cell carcinoma (ESCC) remains uncertain. This exploratory analysis aims to assess the impact of time to surgery (TTS) on perioperative and survival outcomes in patients with advanced ESCC enrolled in the phase III trial JCOG1109. METHODS: Patients who underwent esophagectomy following neoadjuvant chemotherapy or chemoradiotherapy were included. Within each treatment arm, patients were categorized into four TTS subgroups according to cohort quartiles. Perioperative complications, overall survival (OS), and progression-free survival (PFS) were evaluated. RESULTS: The median TTS was 35 (range, 16-81), 38 (17-109), and 41 (14-98) days for the cisplatin plus fluorouracil (CF), docetaxel, cisplatin plus fluorouracil, and CF with radiotherapy (CF-RT) arms, respectively. Baseline characteristics were comparable across the TTS subgroups. Operative time and overall complication rates showed no significant differences. In the CF-RT arm, a longer TTS was associated with increased blood loss (200, 210, 300, and 370 mL) and a trend toward a higher anastomotic leakage (6%, 7%, 14%, and 18%), as well as a trend toward poorer PFS and OS, particularly at more prolonged intervals. However, across all treatment arms, OS and PFS did not differ among the TTS subgroups, with multivariable analysis revealing no consistent associations between TTS and survival. CONCLUSIONS: Time to surgery following neoadjuvant therapy did not significantly influence prognosis in advanced ESCC. Nonetheless, prolonged intervals after chemoradiotherapy may increase surgical complexity and leakage risk, in addition to elevating the potential for adverse prognostic effects associated with excessive delays.
3 个 Figure · 8 个 KM 面板
Fig. 1 Overall survival in the TTS subgroups. Kaplan–Meier curves for overall survival according to quartiles (Q1–Q4) in each treatment arm, with patients stratified into four subgroups within each treatment arm on the basis of TTS distribution quantiles in the overall cohort. a CF arm, b DCF arm, and c CF-RT arm. CF cisplatin plus fluorouracil; DCF docetaxel, cisplatin plus fluorouracil; CF-RT CF with radiotherapy
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel B
Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel C
Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 Progression-free survival in the TTS subgroups. Kaplan–Meier curves for progression-free survival according to quartiles (Q1–Q4) in each treatment arm. a CF arm, b DCF arm, and c CF-RT arm. CF cisplatin plus fluorouracil; DCF docetaxel, cisplatin plus fluorouracil; CF-RT CF with radiotherapy
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel B
Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel C
Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 Overall survival and progression-free survival comparing the Q1-Q3 and Q4 TTS subgroups in the CF-RT arm. Kaplan–Meier curves for overall survival and progression-free survival in the CF-RT arm, comparing patients in the Q1–Q3 TTS subgroups with those in the Q4 subgroup. CF-RT cisplatin plus fluorouracil with radiotherapy